Easton Capital joins £9M Cumulus Oncology investment round
Easton Capital has completed an investment in Cumulus Oncology alongside the Scottish National Investment Bank and a consortium of private investors led by Eos Advisory. The £9M equity investment will support Cumulus’s portfolio of companies dedicated to developing cancer treatments and fast-tracking the development of new drugs from discovery through clinical trials to patient application.
Founded in 2017 by CEO Dr Clare Wareing, Cumulus Oncology is a cancer therapeutics development company. Based in Edinburgh, it is Europe’s first biotech creation studio and drug discovery accelerator specialising in oncology. Cumulus takes a fresh approach to drug development as both the parent and creator of multiple spin-out companies.
Easton Capital provides long term capital investment to support high growth businesses. It is a division of the Easton Group – a family-owned property and investment business with 50 years’ experience of investing in our communities.
“We are very pleased to announce our investment in Cumulus Oncology, and proud to support its development of pioneering cancer treatments.
Cumulus has a unique business model that allows for the scientific validation of oncology therapies to be fast-tracked while de-risking the investment across a portfolio of assets.”
Steven Easton
Director at Easton Group
Easton Group News
Easton Group acquires Andrew Wright Windows
Easton Group has expanded its portfolio with the acquisition of Andrew Wright Windows, securing the future of the long-standing Scottish business.
The Mill opens with modern cosy cafe
Easton Property has let cafe restaurant premises in Dalry to R&M Food Services Ltd. The new venture will trade as The Mill and offer breakfast and…
The Sunday Times Hundred 2025
Easton Capital portfolio company, Green Home Systems, has been listed in The Sunday Times Hundred as one of the UK's fastest growing companies.